Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)可以- fite開始二期試驗治療症狀性角膜炎乾燥(幹眼綜合症)
Wednesday, January 31st, 2007 週三, 2007年1月31日 Can-Fite BioPharma Ltd. (TASE:CFBI) has begun Phase II clinical trials for its CF101 drug for the treatment of symptoms of keratitis sicca (dry-eye syndrome).可以- fite biopharma有限公司( tase : cfbi )已開始二期臨床試驗,其cf101藥物用於治療症狀性角膜炎乾燥(幹眼綜合症) 。
Share This分享此
































